SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.

[1]  A. Dritschilo,et al.  Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer , 2015, Acta oncologica.

[2]  M. Steinberg,et al.  Stereotactic body radiation therapy for prostate cancer: Rational and reasonable. , 2015, Practical radiation oncology.

[3]  M. Ghilezan,et al.  High-dose-rate brachytherapy as monotherapy for prostate cancer. , 2014, Brachytherapy.

[4]  P. Manser,et al.  Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer , 2014, Radiation oncology.

[5]  A. Katz,et al.  Prostate-Specific Antigen Bounce Following Stereotactic Body Radiation Therapy for Prostate Cancer , 2014, Front. Oncol..

[6]  Jason Wang,et al.  Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  I. Hsu,et al.  Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir , 2013, Radiation oncology.

[8]  M. Steinberg,et al.  Clinical Investigation : Genitourinary Cancer Prostate-Specific Antigen Bounce After High-Dose-Rate Monotherapy for Prostate Cancer , 2013 .

[9]  M. Santoro,et al.  Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years , 2013, Radiation oncology.

[10]  M. Zelefsky,et al.  Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? , 2012, The Lancet. Oncology.

[11]  P. Hoskin,et al.  High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. , 2012, International journal of radiation oncology, biology, physics.

[12]  G. Gustafson,et al.  High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[13]  Y. Yamada,et al.  Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. , 2011, Urology.

[14]  E. B. Butler,et al.  Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer. , 2010, Urology.

[15]  M. Eble,et al.  Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  V. Seshan,et al.  Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. , 2009, International journal of radiation oncology, biology, physics.

[17]  J. Ciezki,et al.  Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. , 2009, Urology.

[18]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  J. Brooks,et al.  Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. , 2009, International journal of radiation oncology, biology, physics.

[20]  Louis Potters,et al.  Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. , 2007, International journal of radiation oncology, biology, physics.

[21]  D. Kuban,et al.  PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. , 2004, International journal of radiation oncology, biology, physics.

[22]  C. Fuller,et al.  Early prostate‐specific antigen (PSA) kinetics following prostate carcinoma radiotherapy , 2004, Cancer.

[23]  D. Kuban,et al.  Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. , 2002, International journal of radiation oncology, biology, physics.

[24]  A. Hanlon,et al.  Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. , 1996, The Journal of urology.

[25]  B. Chauvet,et al.  Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A Pollack,et al.  The fall and rise of prostate‐specific antigen: Kinetics of serum prostate‐specific antigen levels after radiation therapy for prostate cancer , 1993, Cancer.

[27]  E. Messing,et al.  Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S Greenland,et al.  Modeling and variable selection in epidemiologic analysis. , 1989, American journal of public health.

[29]  A. Fiorentino,et al.  In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta=1.4 (0.9-2.2) Gy. , 2013, International journal of radiation oncology, biology, physics.

[30]  J. Hendry,et al.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. , 2012, International journal of radiation oncology, biology, physics.

[31]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  D. Brenner,et al.  Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .